ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...
Surveys show vaccine hesitancy among pet owners in the United States is rising, leaving both animals and people at greater risk for zoonotic diseases. On social media, influencers are warning against ...
Accelerated by the COVID-19 pandemic, research is now exploring vaccines capable not only of preventing infections, but also ...
A single enzyme that can generate all four nucleoside triphosphates, the building blocks of ribonucleic acid (RNA), has been ...
In recent years, messenger RNA (mRNA) vaccines have shown significant success in preventing viral and bacterial infections, ...
Hongene Biotech receives grant from Gates Foundation to develop and expand global access to mRNA vaccine raw materials: Singapore Saturday, January 24, 2026, 11:00 Hrs [IST] Honge ...
Key market opportunities in the RNA Therapy Clinical Trials sector include an increase in chronic and rare diseases, advancements in delivery technologies like lipid nanoparticles, robust venture ...
Immunomic Therapeutics, Inc. ("ITI"), a privately held clinical-stage biotechnology company pioneering nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA ...
Hongene Biotech Announces Grant to Expand Global Access to mRNA Vaccine Raw MaterialsSingapore, January 12, 2026: Hongene Biotech today announced the receipt of a grant from the Gates Foundation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results